

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:ssptacmb1647

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

\* \* \* \* \* Welcome to STN International \* \* \* \* \*

NEWS	1			Web Page for STN Seminar Schedule - N. America
NEWS	2	NOV	21	CAS patent coverage to include exemplified prophetic substances identified in English-, French-, German-, and Japanese-language basic patents from 2004-present
NEWS	3	NOV	26	MARPAT enhanced with FSORT command
NEWS	4	NOV	26	CHEMSAFE now available on STN Easy
NEWS	5	NOV	26	Two new SET commands increase convenience of STN searching
NEWS	6	DEC	01	ChemPort single article sales feature unavailable
NEWS	7	DEC	12	GBFULL now offers single source for full-text coverage of complete UK patent families
NEWS	8	DEC	17	Fifty-one pharmaceutical ingredients added to PS
NEWS	9	JAN	06	The retention policy for unread STNmail messages will change in 2009 for STN-Columbus and STN-Tokyo
NEWS	10	JAN	07	WPIDS, WPINDEX, and WPIX enhanced Japanese Patent Classification Data
NEWS	11	FEB	02	Simultaneous left and right truncation (SLART) added for CERAB, COMPUAB, ELCOM, and SOLIDSTATE
NEWS	12	FEB	02	GENBANK enhanced with SET PLURALS and SET SPELLING
NEWS	13	FEB	06	Patent sequence location (PSL) data added to USGENE
NEWS	14	FEB	10	COMPENDEX reloaded and enhanced
NEWS	15	FEB	11	WTEXTILES reloaded and enhanced
NEWS	16	FEB	19	New patent-examiner citations in 300,000 CA/CAPLUS patent records provide insights into related prior art
NEWS	17	FEB	19	Increase the precision of your patent queries -- use terms from the IPC Thesaurus, Version 2009.01
NEWS	18	FEB	23	Several formats for image display and print options discontinued in USPATFULL and USPAT2
NEWS	19	FEB	23	MEDLINE now offers more precise author group fields and 2009 MeSH terms
NEWS	20	FEB	23	TOXCENTER updates mirror those of MEDLINE - more precise author group fields and 2009 MeSH terms
NEWS	21	FEB	23	Three million new patent records blast AEROSPACE into STN patent clusters
NEWS	22	FEB	25	USGENE enhanced with patent family and legal status display data from INPADOCDB
NEWS	23	MAR	06	INPADOCDB and INPAFAMDB enhanced with new display formats
NEWS	24	MAR	11	EPFULL backfile enhanced with additional full-text applications and grants
NEWS	25	MAR	11	ESBIOBASE reloaded and enhanced
NEWS	26	MAR	20	CAS databases on STN enhanced with new super role for nanomaterial substances
NEWS	27	MAR	23	CA/CAPLUS enhanced with more than 250,000 patent equivalents from China

NEWS 28 MAR 30 IMSPATENTS reloaded and enhanced

NEWS EXPRESS JUNE 27 08 CURRENT WINDOWS VERSION IS V8.3,  
AND CURRENT DISCOVER FILE IS DATED 23 JUNE 2008.

NEWS HOURS STN Operating Hours Plus Help Desk Availability  
NEWS LOGIN Welcome Banner and News Items  
NEWS IPC8 For general information regarding STN implementation of IPC 8

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN customer agreement. This agreement limits use to scientific research. Use for software development or design, implementation of commercial gateways, or use of CAS and STN data in the building of commercial products is prohibited and may result in loss of user privileges and other penalties.

\* \* \* \* \* STN Columbus \* \* \* \* \*

FILE 'HOME' ENTERED AT 12:06:59 ON 30 MAR 2009

=> file medline embase biosis caplus

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.22	0.22

FILE 'MEDLINE' ENTERED AT 12:07:20 ON 30 MAR 2009

FILE 'EMBASE' ENTERED AT 12:07:20 ON 30 MAR 2009  
Copyright (c) 2009 Elsevier B.V. All rights reserved.

FILE 'BIOSIS' ENTERED AT 12:07:20 ON 30 MAR 2009  
Copyright (c) 2009 The Thomson Corporation

FILE 'CAPLUS' ENTERED AT 12:07:20 ON 30 MAR 2009  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2009 AMERICAN CHEMICAL SOCIETY (ACS)

=> s Porchet H?/AU

L1 261 PORCHET H?/AU

=> s l1 and prostate

L2 7 L1 AND PROSTATE

=> dup rem l2

PROCESSING COMPLETED FOR L2

L3 4 DUP REM L2 (3 DUPLICATES REMOVED)

=> s Heimgarter F?/AU

L4 0 HEIMGARTER F?/AU

=> s Heimgartner F?/AU

L5 32 HEIMGARTNER F?/AU

=> s l5 and prostate

L6 2 L5 AND PROSTATE

=> dup rem l6

PROCESSING COMPLETED FOR L6

L7 2 DUP REM L6 (0 DUPLICATES REMOVED)

=> s Curdy C?/AU

L8 29 CURDY C?/AU

=> s l8 and prostate

L9 3 L8 AND PROSTATE

=> dup rem l9

PROCESSING COMPLETED FOR L9

L10 3 DUP REM L9 (0 DUPLICATES REMOVED)

=> s Ducrey B?/AU

L11 16 DUCREY B?/AU

=> dup rem l11

PROCESSING COMPLETED FOR L11

L12 10 DUP REM L11 (6 DUPLICATES REMOVED)

=> s l12 and prostate

L13 3 L12 AND PROSTATE

=> dis his

(FILE 'HOME' ENTERED AT 12:06:59 ON 30 MAR 2009)

FILE 'MEDLINE, EMBASE, BIOSIS, CAPLUS' ENTERED AT 12:07:20 ON 30 MAR 2009

L1 261 S PORCHET H?/AU

L2 7 S L1 AND PROSTATE

L3 4 DUP REM L2 (3 DUPLICATES REMOVED)

L4 0 S HEIMGARTER F?/AU

L5 32 S HEIMGARTNER F?/AU

L6 2 S L5 AND PROSTATE

L7 2 DUP REM L6 (0 DUPLICATES REMOVED)

L8 29 S CURDY C?/AU

L9 3 S L8 AND PROSTATE

L10 3 DUP REM L9 (0 DUPLICATES REMOVED)

L11 16 S DUCREY B?/AU

L12 10 DUP REM L11 (6 DUPLICATES REMOVED)

L13 3 S L12 AND PROSTATE

=> dis ibib abs l3 1-4

L3 ANSWER 1 OF 4 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2008:1487237 CAPLUS

DOCUMENT NUMBER: 150:24287

TITLE: Slow release pharmaceutical composition made of microparticles comprising PLGA type copolymer and peptide salt as active substance

INVENTOR(S): Ducrey, Bertrand; Garrouste, Patrick; Curdy, Catherine; Bardet, Marie-Anne; Porchet, Herve ; Lundstrom, Eija; Heimgartner, Frederic

PATENT ASSIGNEE(S): Debio Recherche Pharmaceutique S.A., Switz.

SOURCE: PCT Int. Appl., 19pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
------------	------	------	-----------------	------

WO 2008149320 A2 20081211 WO 2008-IB52241 20080606  
WO 2008149320 A3 20090205

W: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ,  
CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES,  
FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE,  
KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD,  
ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH,  
PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM,  
TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW  
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU,  
IE, IS, IT, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK,  
TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD,  
TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW,  
AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA

PRIORITY APPLN. INFO.: EP 2007-109767 A 20070606  
WO 2007-IB54372 A 20071027

AB Pharmaceutical composition made of microparticles for the slow release of an active substance at least during a period covering the sixth month after injection of said composition, said composition comprising a group of microparticles

made of a copolymer of the PLGA type which incorporate an active substance in the form of a water insol. peptide salt; said copolymer furthermore comprising at least 75% of lactic acid and an inherent viscosity between 0.1 and 0.9 dL/g, as measured in chloroform at 25° and at a polymer concentration of 0.5 g/dL; said microparticles furthermore having a size distribution defined as follows : D(v,0.1) is between 10 and 30 µm, D(v,0.5) is between 30 and 70 µm, D(v,0.9) is between 50 and 110 µm.

L3 ANSWER 2 OF 4 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2005:612107 CAPLUS

DOCUMENT NUMBER: 143:120559

TITLE: Sustained release compositions of gonadotropin hormone releasing hormone and estrogen

INVENTOR(S): Porchet, Herve; Lundstrom, Eija; Curdy, Catherine; Bardet, Marie-Anne

PATENT ASSIGNEE(S): Debiopharm S.A., Switz.

SOURCE: PCT Int. Appl., 30 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005063276	A1	20050714	WO 2004-IB4276	20041223
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			

PRIORITY APPLN. INFO.: WO 2003-IB6159 A 20031223

AB The present invention relates to compns. comprising two sustained release formulations, the first being capable of releasing a gonadotropin releasing hormone composition and the second an estrogenic composition The compns.

of the invention can be employed for an improved androgen deprivation therapy of prostate cancer, in which therapy loss of bone mineral d. and the occurrence and severity of hot flushes are minimized through the maintenance of a minimally adequate estrogen level. Combinations of polyestradiol phosphate and triptorelin were prepared for extemporaneous reconstitution.

REFERENCE COUNT: 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 3 OF 4 CAPLUS COPYRIGHT 2009 ACS on STN  
 ACCESSION NUMBER: 2004:965090 CAPLUS  
 DOCUMENT NUMBER: 141:389284  
 TITLE: Methods and compositions using gonadotropin hormone releasing hormone  
 INVENTOR(S): Porchet, Herve; Heimgartner, Frederic; Curdy, Catherine; Ducrey, Bertrand  
 PATENT ASSIGNEE(S): Debiopharm S.A., Switz.  
 SOURCE: PCT Int. Appl., 33 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004096259	A1	20041111	WO 2004-IB1334	20040430
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2523830	A1	20041111	CA 2004-2523830	20040430
EP 1617859	A1	20060125	EP 2004-730606	20040430
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR				
BR 2004009950	A	20060425	BR 2004-9950	20040430
CN 1780634	A	20060531	CN 2004-80011409	20040430
JP 2006525306	T	20061109	JP 2006-506555	20040430
MX 2005011299	A	20060124	MX 2005-11299	20051020
US 20070042040	A1	20070222	US 2006-554292	20060922
PRIORITY APPLN. INFO.:			WO 2003-IB1680	A 20030430
			WO 2004-IB1334	W 20040430

AB The present invention relates to compns. comprising two sustained release formulations, the first being capable of releasing a gonadotropin releasing hormone composition and the second an estrogenic composition The compns. of the invention can be employed for an improved androgen deprivation therapy of prostate cancer, in which therapy loss of bone mineral d. and the occurrence and severity of hot flashes are minimized through the maintenance of a minimally adequate estrogen level.

REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 4 OF 4 MEDLINE on STN DUPLICATE 1  
 ACCESSION NUMBER: 2003355146 MEDLINE

DOCUMENT NUMBER: PubMed ID: 12887472  
 TITLE: Comparative efficacy of triptorelin pamoate and leuprolide acetate in men with advanced prostate cancer.  
 AUTHOR: Heyns C F; Simonin M-P; Groscurin P; Schall R; Porchet H C  
 CORPORATE SOURCE: Department of Urology, University of Stellenbosch, Tygerberg Hospital, Western Cape, South Africa. (For the South African Triptorelin Study Group). cfh2@sun.ac.za  
 SOURCE: BJU international, (2003 Aug) Vol. 92, No. 3, pp. 226-31. Journal code: 100886721. ISSN: 1464-4096.  
 PUB. COUNTRY: England: United Kingdom  
 DOCUMENT TYPE: (CLINICAL TRIAL)  
 (COMPARATIVE STUDY)  
 Journal; Article; (JOURNAL ARTICLE)  
 (MULTICENTER STUDY)  
 (RANDOMIZED CONTROLLED TRIAL)  
 (RESEARCH SUPPORT, NON-U.S. GOV'T)  
 LANGUAGE: English  
 FILE SEGMENT: Priority Journals  
 ENTRY MONTH: 200309  
 ENTRY DATE: Entered STN: 31 Jul 2003  
 Last Updated on STN: 5 Sep 2003  
 Entered Medline: 4 Sep 2003

AB OBJECTIVE: To compare the efficacy of monthly administrations of the luteinizing hormone-releasing hormone agonists triptorelin pamoate and leuprolide acetate to induce and maintain castrate levels of serum testosterone in men with advanced prostate cancer. PATIENTS AND METHODS: Men with advanced prostate cancer were randomly assigned to receive triptorelin 3.75 mg or leuprolide 7.5 mg. The agent was injected intramuscularly every 28 days for nine injections. Primary endpoints were the percentages of men whose serum testosterone concentrations declined to and were maintained at or below castrate levels ( $\leq 1.735$  nmol/L or  $\leq 500$  ng/L) during 9 months (253 days) of treatment. Secondary endpoints were luteinizing hormone levels, bone pain, prostate specific antigen levels, quality of life, testosterone pharmacodynamics, survival, and safety variables. RESULTS: In all, 284 men received either triptorelin (140) or leuprolide (144). The percentage of men with castrate levels of serum testosterone was lower at 29 days for triptorelin than for leuprolide (91.2% vs 99.3%; point estimate - 8.0, 95% confidence interval - 16.9% to - 1.4%), but equivalent at 57 days (97.7% vs 97.1%). The mean (98.8% vs 97.3%) and cumulative (96.2% vs 91.2%) castration maintenance rates between 29 and 253 days were equivalent between the treatment groups. Secondary endpoints were equivalent between treatment groups except for the 9-month survival rate, which was significantly higher for triptorelin than for leuprolide (97.0% vs 90.5%;  $P = 0.033$ ). Both treatments were well tolerated. CONCLUSION: Triptorelin reduced testosterone concentrations less rapidly, but maintained castration as effectively as leuprolide. There was no evidence that the slower onset of castration caused deleterious effects.

=> FIL STNGUIDE

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	36.82	37.04
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-2.46	-2.46

FILE 'STNGUIDE' ENTERED AT 12:11:28 ON 30 MAR 2009  
 USE IS SUBJECT TO THE TERMS OF YOUR CUSTOMER AGREEMENT

COPYRIGHT (C) 2009 AMERICAN CHEMICAL SOCIETY (ACS)

FILE CONTAINS CURRENT INFORMATION.

LAST RELOADED: Mar 27, 2009 (20090327/UP).

=> dis his

(FILE 'HOME' ENTERED AT 12:06:59 ON 30 MAR 2009)

FILE 'MEDLINE, EMBASE, BIOSIS, CAPLUS' ENTERED AT 12:07:20 ON 30 MAR 2009

L1 261 S PORCHET H?/AU  
L2 7 S L1 AND PROSTATE  
L3 4 DUP REM L2 (3 DUPLICATES REMOVED)  
L4 0 S HEIMGARTER F?/AU  
L5 32 S HEIMGARTNER F?/AU  
L6 2 S L5 AND PROSTATE  
L7 2 DUP REM L6 (0 DUPLICATES REMOVED)  
L8 29 S CURDY C?/AU  
L9 3 S L8 AND PROSTATE  
L10 3 DUP REM L9 (0 DUPLICATES REMOVED)  
L11 16 S DUCREY B?/AU  
L12 10 DUP REM L11 (6 DUPLICATES REMOVED)  
L13 3 S L12 AND PROSTATE

FILE 'STNGUIDE' ENTERED AT 12:11:28 ON 30 MAR 2009

=> dis ibib abs l6 1-2

YOU HAVE REQUESTED DATA FROM FILE 'CAPLUS' - CONTINUE? (Y)/N:y

L6 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2008:1487237 CAPLUS

DOCUMENT NUMBER: 150:24287

TITLE: Slow release pharmaceutical composition made of microparticles comprising PLGA type copolymer and peptide salt as active substance

INVENTOR(S): Ducrey, Bertrand; Garrouste, Patrick; Curdy, Catherine; Bardet, Marie-Anne; Porchet, Herve; Lundstrom, Eija; Heimgartner, Frederic

PATENT ASSIGNEE(S): Debio Recherche Pharmaceutique S.A., Switz.

SOURCE: PCT Int. Appl., 19pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2008149320	A2	20081211	WO 2008-IB52241	20080606
WO 2008149320	A3	20090205		
W:	AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW			
RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK,			

TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD,  
 TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW,  
 AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA

PRIORITY APPLN. INFO.: EP 2007-109767 A 20070606  
 WO 2007-IB54372 A 20071027

AB Pharmaceutical composition made of microparticles for the slow release of an active substance at least during a period covering the sixth month after injection of said composition, said composition comprising a group of microparticles

made of a copolymer of the PLGA type which incorporate an active substance in the form of a water insol. peptide salt; said copolymer furthermore comprising at least 75% of lactic acid and an inherent viscosity between 0.1 and 0.9 dL/g, as measured in chloroform at 25° and at a polymer concentration of 0.5 g/dL; said microparticles furthermore having a size distribution defined as follows : D(v,0.1) is between 10 and 30 µm, D(v,0.5) is between 30 and 70 µm, D(v,0.9) is between 50 and 110 µm.

L6 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2004:965090 CAPLUS

DOCUMENT NUMBER: 141:389284

TITLE: Methods and compositions using gonadotropin hormone releasing hormone

INVENTOR(S): Porchet, Herve; Heimgartner, Frederic;  
 Curdy, Catherine; Ducrey, Bertrand

PATENT ASSIGNEE(S): Debiopharm S.A., Switz.

SOURCE: PCT Int. Appl., 33 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004096259	A1	20041111	WO 2004-IB1334	20040430
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2523830	A1	20041111	CA 2004-2523830	20040430
EP 1617859	A1	20060125	EP 2004-730606	20040430
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR				
BR 2004009950	A	20060425	BR 2004-9950	20040430
CN 1780634	A	20060531	CN 2004-80011409	20040430
JP 2006525306	T	20061109	JP 2006-506555	20040430
MX 2005011299	A	20060124	MX 2005-11299	20051020
US 20070042040	A1	20070222	US 2006-554292	20060922

PRIORITY APPLN. INFO.: WO 2003-IB1680 A 20030430  
 WO 2004-IB1334 W 20040430

AB The present invention relates to compns. comprising two sustained release formulations, the first being capable of releasing a gonadotropin releasing hormone composition and the second an estrogenic composition The compns. of the invention can be employed for an improved androgen deprivation



therapy of prostate cancer, in which therapy loss of bone mineral d. and the occurrence and severity of hot flashes are minimized through the maintenance of a minimally adequate estrogen level.  
REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> dis his

(FILE 'HOME' ENTERED AT 12:06:59 ON 30 MAR 2009)

FILE 'MEDLINE, EMBASE, BIOSIS, CAPLUS' ENTERED AT 12:07:20 ON 30 MAR 2009

L1 261 S PORCHET H?/AU  
L2 7 S L1 AND PROSTATE  
L3 4 DUP REM L2 (3 DUPLICATES REMOVED)  
L4 0 S HEIMGARTER F?/AU  
L5 32 S HEIMGARTNER F?/AU  
L6 2 S L5 AND PROSTATE  
L7 2 DUP REM L6 (0 DUPLICATES REMOVED)  
L8 29 S CURDY C?/AU  
L9 3 S L8 AND PROSTATE  
L10 3 DUP REM L9 (0 DUPLICATES REMOVED)  
L11 16 S DUCREY B?/AU  
L12 10 DUP REM L11 (6 DUPLICATES REMOVED)  
L13 3 S L12 AND PROSTATE

FILE 'STNGUIDE' ENTERED AT 12:11:28 ON 30 MAR 2009

FILE 'CAPLUS' ENTERED AT 12:12:35 ON 30 MAR 2009

FILE 'STNGUIDE' ENTERED AT 12:12:35 ON 30 MAR 2009

=> dis ibib abs l10 1-3

YOU HAVE REQUESTED DATA FROM FILE 'CAPLUS' - CONTINUE? (Y)/N:y

L10 ANSWER 1 OF 3 CAPLUS COPYRIGHT 2009 ACS on STN  
ACCESSION NUMBER: 2008:1487237 CAPLUS  
DOCUMENT NUMBER: 150:24287  
TITLE: Slow release pharmaceutical composition made of microparticles comprising PLGA type copolymer and peptide salt as active substance  
INVENTOR(S): Ducrey, Bertrand; Garrouste, Patrick; Curdy, Catherine; Bardet, Marie-Anne; Porchet, Herve; Lundstrom, Eija; Heimgartner, Frederic  
PATENT ASSIGNEE(S): Debio Recherche Pharmaceutique S.A., Switz.  
SOURCE: PCT Int. Appl., 19pp.  
CODEN: PIXXD2  
DOCUMENT TYPE: Patent  
LANGUAGE: English  
FAMILY ACC. NUM. COUNT: 1  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	----	-----	-----	-----
WO 2008149320	A2	20081211	WO 2008-IB52241	20080606
WO 2008149320	A3	20090205		
W:	AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE,			

KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD,  
 ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH,  
 PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM,  
 TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW  
 RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU,  
 IE, IS, IT, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK,  
 TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD,  
 TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW,  
 AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA

PRIORITY APPLN. INFO.: EP 2007-109767 A 20070606  
 WO 2007-IB54372 A 20071027

AB Pharmaceutical composition made of microparticles for the slow release of an active substance at least during a period covering the sixth month after injection of said composition, said composition comprising a group of microparticles

made of a copolymer of the PLGA type which incorporate an active substance in the form of a water insol. peptide salt; said copolymer furthermore comprising at least 75% of lactic acid and an inherent viscosity between 0.1 and 0.9 dL/g, as measured in chloroform at 25° and at a polymer concentration of 0.5 g/dL; said microparticles furthermore having a size distribution defined as follows : D(v,0.1) is between 10 and 30 µm, D(v,0.5) is between 30 and 70 µm, D(v,0.9) is between 50 and 110 µm.

L10 ANSWER 2 OF 3 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2005:612107 CAPLUS

DOCUMENT NUMBER: 143:120559

TITLE: Sustained release compositions of gonadotropin hormone releasing hormone and estrogen

INVENTOR(S): Porchet, Herve; Lundstrom, Eija; Curdy, Catherine; Bardet, Marie-Anne

PATENT ASSIGNEE(S): Debiopharm S.A., Switz.

SOURCE: PCT Int. Appl., 30 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005063276	A1	20050714	WO 2004-IB4276	20041223
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			

PRIORITY APPLN. INFO.: WO 2003-IB6159 A 20031223

AB The present invention relates to compns. comprising two sustained release formulations, the first being capable of releasing a gonadotropin releasing hormone composition and the second an estrogenic composition The compns.

of the invention can be employed for an improved androgen deprivation therapy of prostate cancer, in which therapy loss of bone mineral d. and the occurrence and severity of hot flushes are minimized through the maintenance of a minimally adequate estrogen level. Combinations of polyestradiol phosphate and triptorelin were prepared for

extemporaneous reconstitution.

REFERENCE COUNT: 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2004:965090 CAPLUS

DOCUMENT NUMBER: 141:389284

TITLE: Methods and compositions using gonadotropin hormone releasing hormone

INVENTOR(S): Porchet, Herve; Heimgartner, Frederic; Curdy, Catherine; Ducrey, Bertrand

PATENT ASSIGNEE(S): Debiopharm S.A., Switz.

SOURCE: PCT Int. Appl., 33 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004096259	A1	20041111	WO 2004-IB1334	20040430
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
CA 2523830	A1	20041111	CA 2004-2523830	20040430
EP 1617859	A1	20060125	EP 2004-730606	20040430
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR			
BR 2004009950	A	20060425	BR 2004-9950	20040430
CN 1780634	A	20060531	CN 2004-80011409	20040430
JP 2006525306	T	20061109	JP 2006-506555	20040430
MX 2005011299	A	20060124	MX 2005-11299	20051020
US 20070042040	A1	20070222	US 2006-554292	20060922
PRIORITY APPLN. INFO.:			WO 2003-IB1680	A 20030430
			WO 2004-IB1334	W 20040430

AB The present invention relates to compns. comprising two sustained release formulations, the first being capable of releasing a gonadotropin releasing hormone composition and the second an estrogenic composition The compns.

of the invention can be employed for an improved androgen deprivation therapy of prostate cancer, in which therapy loss of bone mineral d. and the occurrence and severity of hot flashes are minimized through the maintenance of a minimally adequate estrogen level.

REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> dis his

(FILE 'HOME' ENTERED AT 12:06:59 ON 30 MAR 2009)

FILE 'MEDLINE, EMBASE, BIOSIS, CAPLUS' ENTERED AT 12:07:20 ON 30 MAR 2009

L1 261 S PORCHET H?/AU

L2 7 S L1 AND PROSTATE  
 L3 4 DUP REM L2 (3 DUPLICATES REMOVED)  
 L4 0 S HEIMGARTER F?/AU  
 L5 32 S HEIMGARTNER F?/AU  
 L6 2 S L5 AND PROSTATE  
 L7 2 DUP REM L6 (0 DUPLICATES REMOVED)  
 L8 29 S CURDY C?/AU  
 L9 3 S L8 AND PROSTATE  
 L10 3 DUP REM L9 (0 DUPLICATES REMOVED)  
 L11 16 S DUCREY B?/AU  
 L12 10 DUP REM L11 (6 DUPLICATES REMOVED)  
 L13 3 S L12 AND PROSTATE

FILE 'STNGUIDE' ENTERED AT 12:11:28 ON 30 MAR 2009

FILE 'CAPLUS' ENTERED AT 12:12:35 ON 30 MAR 2009

FILE 'STNGUIDE' ENTERED AT 12:12:35 ON 30 MAR 2009

FILE 'CAPLUS' ENTERED AT 12:13:17 ON 30 MAR 2009

FILE 'STNGUIDE' ENTERED AT 12:13:17 ON 30 MAR 2009

=> dis ibib abs l13 1-3

YOU HAVE REQUESTED DATA FROM FILE 'EMBASE, CAPLUS' - CONTINUE? (Y)/N:y

L13 ANSWER 1 OF 3 EMBASE COPYRIGHT (c) 2009 Elsevier B.V. All rights reserved on STN  
 ACCESSION NUMBER: 1994361901 EMBASE  
 TITLE: [Current research on medicinal plants].  
 RECHERCHE ACTUELLE DANS LE DOMAINE DES PLANTES MEDICINALES.  
 AUTHOR: Ducrey, B. (correspondence)  
 CORPORATE SOURCE: Insti. de Pharmacognosie/Phytochimie, Universite de  
 Lausanne, BEP, 1015 Lausanne-Dorigny, Switzerland.  
 SOURCE: Schweizer Apothekerzeitung, (1994) Vol. 132, No. 24, pp.  
 646-649.  
 ISSN: 0036-7508 CODEN: SAPOEF  
 COUNTRY: Switzerland  
 DOCUMENT TYPE: Journal; Conference Article; (Conference paper)  
 FILE SEGMENT: 016 Cancer  
 030 Clinical and Experimental Pharmacology  
 037 Drug Literature Index  
 004 Microbiology: Bacteriology, Mycology, Parasitology  
 and Virology  
 LANGUAGE: French  
 SUMMARY LANGUAGE: French  
 ENTRY DATE: Entered STN: 29 Dec 1994  
 Last Updated on STN: 29 Dec 1994

L13 ANSWER 2 OF 3 CAPLUS COPYRIGHT 2009 ACS on STN  
 ACCESSION NUMBER: 2008:1487237 CAPLUS  
 DOCUMENT NUMBER: 150:24287  
 TITLE: Slow release pharmaceutical composition made of  
 microparticles comprising PLGA type copolymer and  
 peptide salt as active substance  
 INVENTOR(S): Ducrey, Bertrand; Garrouste, Patrick; Curdy,  
 Catherine; Bardet, Marie-Anne; Porchet, Herve;  
 Lundstrom, Eija; Heimgartner, Frederic  
 PATENT ASSIGNEE(S): Debio Recherche Pharmaceutique S.A., Switz.

SOURCE: PCT Int. Appl., 19pp.  
CODEN: PIXXD2  
DOCUMENT TYPE: Patent  
LANGUAGE: English  
FAMILY ACC. NUM. COUNT: 1  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2008149320	A2	20081211	WO 2008-IB52241	20080606
WO 2008149320	A3	20090205		
W:	AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW			
RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA			

PRIORITY APPLN. INFO.: EP 2007-109767 A 20070606  
WO 2007-IB54372 A 20071027

AB Pharmaceutical composition made of microparticles for the slow release of an active substance at least during a period covering the sixth month after injection of said composition, said composition comprising a group of microparticles

made of a copolymer of the PLGA type which incorporate an active substance in the form of a water insol. peptide salt; said copolymer furthermore comprising at least 75% of lactic acid and an inherent viscosity between 0.1 and 0.9 dL/g, as measured in chloroform at 25° and at a polymer concentration of 0.5 g/dL; said microparticles furthermore having a size distribution defined as follows : D(v,0.1) is between 10 and 30 µm, D(v,0.5) is between 30 and 70 µm, D(v,0.9) is between 50 and 110 µm.

L13 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2004:965090 CAPLUS  
DOCUMENT NUMBER: 141:389284  
TITLE: Methods and compositions using gonadotropin hormone releasing hormone  
INVENTOR(S): Porchet, Herve; Heimgartner, Frederic; Curdy, Catherine; Ducrey, Bertrand  
PATENT ASSIGNEE(S): Debiopharm S.A., Switz.  
SOURCE: PCT Int. Appl., 33 pp.  
CODEN: PIXXD2  
DOCUMENT TYPE: Patent  
LANGUAGE: English  
FAMILY ACC. NUM. COUNT: 1  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004096259	A1	20041111	WO 2004-IB1334	20040430
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM,			

AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK,  
 EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE,  
 SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE,  
 SN, TD, TG

CA 2523830	A1	20041111	CA 2004-2523830	20040430
EP 1617859	A1	20060125	EP 2004-730606	20040430
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR				
BR 2004009950	A	20060425	BR 2004-9950	20040430
CN 1780634	A	20060531	CN 2004-80011409	20040430
JP 2006525306	T	20061109	JP 2006-506555	20040430
MX 2005011299	A	20060124	MX 2005-11299	20051020
US 20070042040	A1	20070222	US 2006-554292	20060922
PRIORITY APPLN. INFO.:			WO 2003-IB1680	A 20030430
			WO 2004-IB1334	W 20040430

AB The present invention relates to compns. comprising two sustained release formulations, the first being capable of releasing a gonadotropin releasing hormone composition and the second an estrogenic composition The compns.

of the invention can be employed for an improved androgen deprivation therapy of prostate cancer, in which therapy loss of bone mineral d. and the occurrence and severity of hot flashes are minimized through the maintenance of a minimally adequate estrogen level.

REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> logoff

ALL L# QUERIES AND ANSWER SETS ARE DELETED AT LOGOFF

LOGOFF? (Y)/N/HOLD:y

COST IN U.S. DOLLARS

SINCE FILE	TOTAL
ENTRY	SESSION
0.07	65.91

FULL ESTIMATED COST

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE	TOTAL
ENTRY	SESSION
0.00	-8.20

CA SUBSCRIBER PRICE

STN INTERNATIONAL LOGOFF AT 12:14:25 ON 30 MAR 2009